Brought to you by 
Strakan, ProSkelia merge in stock swap
01 Jul 2004
Executive Summary
To create a specialty pharmaco with greater R&D capabilities and a larger European sales force, privately held therapeutic development companies Strakan Group Ltd. (bone and skin disease) and ProSkelia SAS (musculoskeletal and hormone disorders) will merge in a stock swap. Each company will hold an equal share in the new entity, which is expected to file for an IPO within a year. Warburg Pincus, which owns over 37% of Strakan, and about 60% of ProSkelia, will have a 50% interest in the combined entity.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Strakan, ProSkelia merge in stock swap
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice